Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Glomerulonephritis Treatment Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Glomerulonephritis Treatment Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 ACH-5228
      • 1.3.3 AMY-101
      • 1.3.4 Atacicept
      • 1.3.5 Avacopan
      • 1.3.6 AVX-002
    • 1.4 Market Segment by Application
      • 1.4.1 Global Glomerulonephritis Treatment Market Share by Application (2019-2025)
      • 1.4.2 Home Care
      • 1.4.3 Clinic
      • 1.4.4 Hospital
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Glomerulonephritis Treatment Market Size
      • 2.1.1 Global Glomerulonephritis Treatment Revenue 2014-2025
      • 2.1.2 Global Glomerulonephritis Treatment Sales 2014-2025
    • 2.2 Glomerulonephritis Treatment Growth Rate by Regions
      • 2.2.1 Global Glomerulonephritis Treatment Sales by Regions 2014-2019
      • 2.2.2 Global Glomerulonephritis Treatment Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Glomerulonephritis Treatment Sales by Manufacturers
      • 3.1.1 Glomerulonephritis Treatment Sales by Manufacturers 2014-2019
      • 3.1.2 Glomerulonephritis Treatment Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Glomerulonephritis Treatment Revenue by Manufacturers (2014-2019)
      • 3.2.2 Glomerulonephritis Treatment Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Glomerulonephritis Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.3 Glomerulonephritis Treatment Price by Manufacturers
    • 3.4 Key Manufacturers Glomerulonephritis Treatment Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Glomerulonephritis Treatment Market
    • 3.6 Key Manufacturers Glomerulonephritis Treatment Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 ACH-5228 Sales and Revenue (2014-2019)
      • 4.1.2 AMY-101 Sales and Revenue (2014-2019)
      • 4.1.3 Atacicept Sales and Revenue (2014-2019)
      • 4.1.4 Avacopan Sales and Revenue (2014-2019)
      • 4.1.5 AVX-002 Sales and Revenue (2014-2019)
    • 4.2 Global Glomerulonephritis Treatment Sales Market Share by Type
    • 4.3 Global Glomerulonephritis Treatment Revenue Market Share by Type
    • 4.4 Glomerulonephritis Treatment Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Glomerulonephritis Treatment Sales by Application

    6 United States

    • 6.1 United States Glomerulonephritis Treatment Breakdown Data by Company
    • 6.2 United States Glomerulonephritis Treatment Breakdown Data by Type
    • 6.3 United States Glomerulonephritis Treatment Breakdown Data by Application

    7 European Union

    • 7.1 European Union Glomerulonephritis Treatment Breakdown Data by Company
    • 7.2 European Union Glomerulonephritis Treatment Breakdown Data by Type
    • 7.3 European Union Glomerulonephritis Treatment Breakdown Data by Application

    8 China

    • 8.1 China Glomerulonephritis Treatment Breakdown Data by Company
    • 8.2 China Glomerulonephritis Treatment Breakdown Data by Type
    • 8.3 China Glomerulonephritis Treatment Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Glomerulonephritis Treatment Breakdown Data by Company
    • 9.2 Rest of World Glomerulonephritis Treatment Breakdown Data by Type
    • 9.3 Rest of World Glomerulonephritis Treatment Breakdown Data by Application
    • 9.4 Rest of World Glomerulonephritis Treatment Breakdown Data by Countries
      • 9.4.1 Rest of World Glomerulonephritis Treatment Sales by Countries
      • 9.4.2 Rest of World Glomerulonephritis Treatment Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Achillion Pharmaceuticals Inc
      • 10.1.1 Achillion Pharmaceuticals Inc Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Glomerulonephritis Treatment
      • 10.1.4 Glomerulonephritis Treatment Product Introduction
      • 10.1.5 Achillion Pharmaceuticals Inc Recent Development
    • 10.2 Anthera Pharmaceuticals Inc
      • 10.2.1 Anthera Pharmaceuticals Inc Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Glomerulonephritis Treatment
      • 10.2.4 Glomerulonephritis Treatment Product Introduction
      • 10.2.5 Anthera Pharmaceuticals Inc Recent Development
    • 10.3 Biogen Inc
      • 10.3.1 Biogen Inc Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Glomerulonephritis Treatment
      • 10.3.4 Glomerulonephritis Treatment Product Introduction
      • 10.3.5 Biogen Inc Recent Development
    • 10.4 Bristol-Myers Squibb Company
      • 10.4.1 Bristol-Myers Squibb Company Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Glomerulonephritis Treatment
      • 10.4.4 Glomerulonephritis Treatment Product Introduction
      • 10.4.5 Bristol-Myers Squibb Company Recent Development
    • 10.5 Cellmid Ltd
      • 10.5.1 Cellmid Ltd Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Glomerulonephritis Treatment
      • 10.5.4 Glomerulonephritis Treatment Product Introduction
      • 10.5.5 Cellmid Ltd Recent Development
    • 10.6 ChemoCentryx Inc
      • 10.6.1 ChemoCentryx Inc Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Glomerulonephritis Treatment
      • 10.6.4 Glomerulonephritis Treatment Product Introduction
      • 10.6.5 ChemoCentryx Inc Recent Development
    • 10.7 Complexa Inc
      • 10.7.1 Complexa Inc Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Glomerulonephritis Treatment
      • 10.7.4 Glomerulonephritis Treatment Product Introduction
      • 10.7.5 Complexa Inc Recent Development
    • 10.8 Dimerix Bioscience Pty Ltd
      • 10.8.1 Dimerix Bioscience Pty Ltd Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Glomerulonephritis Treatment
      • 10.8.4 Glomerulonephritis Treatment Product Introduction
      • 10.8.5 Dimerix Bioscience Pty Ltd Recent Development
    • 10.9 GlaxoSmithKline Plc
      • 10.9.1 GlaxoSmithKline Plc Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Glomerulonephritis Treatment
      • 10.9.4 Glomerulonephritis Treatment Product Introduction
      • 10.9.5 GlaxoSmithKline Plc Recent Development
    • 10.10 Merck KGaA
      • 10.10.1 Merck KGaA Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Glomerulonephritis Treatment
      • 10.10.4 Glomerulonephritis Treatment Product Introduction
      • 10.10.5 Merck KGaA Recent Development
    • 10.11 Omeros Corp
    • 10.12 Pfizer Inc
    • 10.13 Pharmalink AB
    • 10.14 Ra Pharmaceuticals Inc
    • 10.15 Retrophin Inc
    • 10.16 Rigel Pharmaceuticals Inc
    • 10.17 Shire Plc
    • 10.18 Visterra Inc

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Glomerulonephritis Treatment Sales Channels
      • 11.2.2 Glomerulonephritis Treatment Distributors
    • 11.3 Glomerulonephritis Treatment Customers

    12 Market Forecast

    • 12.1 Global Glomerulonephritis Treatment Sales and Revenue Forecast 2019-2025
    • 12.2 Global Glomerulonephritis Treatment Sales Forecast by Type
    • 12.3 Global Glomerulonephritis Treatment Sales Forecast by Application
    • 12.4 Glomerulonephritis Treatment Forecast by Regions
      • 12.4.1 Global Glomerulonephritis Treatment Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Glomerulonephritis Treatment Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      In 2019, the market size of Glomerulonephritis Treatment is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Glomerulonephritis Treatment.

      This report studies the global market size of Glomerulonephritis Treatment, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Glomerulonephritis Treatment sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Achillion Pharmaceuticals Inc
      Anthera Pharmaceuticals Inc
      Biogen Inc
      Bristol-Myers Squibb Company
      Cellmid Ltd
      ChemoCentryx Inc
      Complexa Inc
      Dimerix Bioscience Pty Ltd
      GlaxoSmithKline Plc
      Merck KGaA
      Omeros Corp
      Pfizer Inc
      Pharmalink AB
      Ra Pharmaceuticals Inc
      Retrophin Inc
      Rigel Pharmaceuticals Inc
      Shire Plc
      Visterra Inc

      Market Segment by Product Type
      ACH-5228
      AMY-101
      Atacicept
      Avacopan
      AVX-002

      Market Segment by Application
      Home Care
      Clinic
      Hospital

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Glomerulonephritis Treatment status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Glomerulonephritis Treatment manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Glomerulonephritis Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now